REPLY
28.9.2021 09:32:12 CEST | Business Wire | Press release
On the 15th of October 2021, Reply will launch the fourth edition of the Reply Cyber Security Challenge, a team-based coding competition open to young professionals and cyber security enthusiasts from all over the world.
This year’s edition will be supported by Intesa Sanpaolo, one of the top banking groups in Europe, and Immersive Labs, the platform empowering businesses to increase, measure and evidence human capability in every part of their cybersecurity.
Intesa Sanpaolo‘s support confirms its commitment to increase education, awareness and training on cybersecurity among young people.
Improving cybersecurity knowledge, skills and judgement is Immersive Labs’ mission and the Reply Cyber Security Challenge represents a new and engaging way to power up people’s cyber capabilities.
The challenge, which in 2020 welcomed more than 10,000 participants from 160 countries gather together in 2,380 teams, aims to put teams (from 2 to 4 players) in competition in a 24-hour marathon, Capture The Flag (CTF) challenge, focusing on the identification of vulnerabilities purposely hidden within software and computer systems.
Developed by Reply's Cyber Security experts, the challenge is comprised of five gaming categories (Coding, Web, Binary, Crypto and Miscellaneous) in which participants will have to try to solve, in the shortest time possible, security problems and riddles of increasing difficulty.
The competition will be held on Friday, October 15 , during the European Cyber Security Month (ECSM) , the European awareness campaign that every year, in October, aims to raise the awareness of citizens, organizations, companies and institutions about the major cyber risks.
The podium will be composed by the top three teams that, at the end of the competition, achieve the highest score and present a report showing the strategies they adopted during the challenge. The final score will be determined by the highest number of hidden flags identified plus a bonus awarded for the quick resolution of the problems.
From today and until October 15th , at the website challenges.reply.com , participants will have the opportunity to register for the challenge for free (by registering their team or joining other players in random teams) and to train in "sandbox" mode on the challenges of previous editions.
The Reply Cyber Security Challenge is also enriched with the Train&Win program. Starting today, teachers and students of more than 16 years will be able to train together with problems to solve in CTF mode on the challenges.reply.com platform and win Reply gadgets for educational purposes. The platform becomes a cyber security gym, with exercises and study materials made available to help prepare for the international competition on October 15th .
The Cyber Security Challenge is part of Reply’s Challenges programme, which aims to target the most innovative trends in coding creativity, cyber security and finance. Since 2018, more than 100,000 people have joined the Reply Challenges community.
°°°
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in designing and implementing solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models supported by big data, cloud computing, digital media and IoT (internet of things). Reply provides consulting, system integration and digital services to organisations across the telecom and media, industry and services, banking and insurance; and public sectors. www.reply.com
Immersive Labs
Immersive Labs is empowering organizations to equip, exercise, and evidence human cyber capabilities. We provide metrics that give security leaders insight into human cyber skills and readiness levels across their organization and improve these through dynamic labs and crisis scenarios that track the threat landscape. Immersive Labs is backed by Goldman Sachs Asset Management, Summit Partners, Insight Partners, Citi Ventures, and Menlo Ventures. Our customers include some of the largest companies in financial services, healthcare, and government, amongst others. For more information on Immersive Labs’ offering, please visit www.immersivelabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005093/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom